Company news
Sunshine Lake Pharma Co., Ltd. Class H (HKEX:6887) news
Sunshine Lake Pharma Co., Ltd. Class H news releases on 6ix. Latest, Oct 2, 2026: Next Day Disclosure Return
Press releases & updates
Next Day Disclosure Return
October 2, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Interim Report 2026
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
May 4, 2026
Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion
August 5, 2025